SavranTech announced today that it has been granted a new U.S. patent titled “Particle Capture Systems and Methods” (U.S. Patent No. US 12,434,243), further strengthening the company’s intellectual property portfolio supporting its proprietary cell-based diagnostics platform.

The newly awarded patent covers automated systems and methods for the capture and processing of rare biological cells from complex samples. This technology underpins SavranTech’s approach to highly sensitive, non-invasive diagnostics, enabling reliable detection of clinically meaningful signals at very low abundance.

SavranTech continues to build a robust intellectual property portfolio to support the development and commercialization of its diagnostic assays across women’s health, prenatal care, and oncology.